Structure-activity relationships: Analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication

Journal of Medicinal Chemistry

Volumn 42, Issue 3, 1999, Pages 497-509

  King, Peter J ^a   Ma, Guoxiang ^c   Miao, Wenfang ^c   Jia, Qi ^c   McDougall, Brenda R ^b   Reinecke, Manfred G ^c   Cornell, Chris ^a   Kuan, Jean ^b   Kim, Tracey R ^b   Robinson Jr , W Edward ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TEXAS CHRISTIAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BIS(3,4 DIHYDROXYBENZOYL) LEVO TARTARIC ACID; BIS(3,4 DIHYDROXYDIHYDROCINNAMOYL) LEVO TARTARIC ACID; BIS(3,4 DIHYDROXYPHENYLACETYL) LEVO TARTARIC ACID; DEXTRO CHICORIC ACID; DICAFFEOYLGLYCERIC ACID; DICAFFEOYLQUINIC ACID; DICAFFEOYLTARTARIC ACID; DIGALLOYL LEVO TARTARIC ACID; MESO CHICORIC ACID; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; BASE SEQUENCE; CAFFEIC ACIDS; CELL LINE; CELL SURVIVAL; CHLOROGENIC ACID; CLONING, MOLECULAR; DNA PRIMERS; DRUG RESISTANCE, MICROBIAL; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINATES; TARTRATES; VIRUS REPLICATION;

EID: 0032972042     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9804735     Document Type: Article

References (47)

1. Engelman, A.; Englund, G.; Orenstein, J. M.; Martin, M. A.; Craigie, R. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J. Virol. 1995, 69, 2729-2736.
2. LaFemina, R. L.; Schneider, C. L.; Robbins, H. L.; Callahan, P. L.; LeGrow, K.; Roth, E.; Schleif, W. A.; Emini, E. A. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J. Virol. 1992, 66, 7414-7419.
3. Roth, M. J.; Schwartzberg, P.; Tanese, N.; Goff, S. P. Analysis of mutations in the integration function of Moloney murine leukemia virus: effect on DNA binding and cutting. J. Virol. 1990, 64, 4709-4717.
4. Sakai, H.; Kawamura, M.; Sakuragi, J.; Sakuragi, S.; Shibata, R.; Ishimoto, A.; Ono, N.; Ueda, S.; Adachi, A. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J. Virol. 1993, 67, 1169-1174.
5. Shin, C. G.; Taddeo, B.; Haseltine, W. A.; Farnet, C. M. Genetic analysis of the human immunodeficiency virus type 1 integrase protein. J. Virol. 1994, 68, 1633-1642.
6. Robinson, W. E., Jr. HIV integrase: the next target? Infect. Med. 1998, 15, 129-137.
7. Robinson, W. E., Jr.; Reinecke, M. G.; Abdel-Malek, S.; Jia, Q.; Chow, S. A. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6326-6331.
8. Robinson, W. E., Jr.; Cordeiro, M.; Abdel-Malek, S.; Jia, Q.; Chow, S. A.; Reinecke, M. G.; Mitchell, W. M. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus (HIV) integrase: Inhibition of the core catalytic domain of HIV integrase. Mol. Pharmacol. 1996, 50, 846-855.
9. McDougall, B.; King, P. J.; Wu, B. W.; Hostomsky, Z.; Reinecke, M. G.; Robinson, W. E., Jr. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob. Agents Chemother. 1998, 42, 140-146.
10. Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Nicklaus, M. C.; Milne, G. W. A.; Proksa, B.; Pommier, Y. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J. Med. Chem. 1997, 40, 942-951.
11. Neamati, N.; Hong, H.; Sunder, S.; Milne, G. W.; Pommier, Y. Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a four-point pharmacophore and tetracyclines as novel inhibitors. Mol. Pharmacol. 1997, 52, 1041-1055.
12. Chow, S. A. In vitro assays for activities of retroviral integrase. Methods: Companion Methods Enzymol. 1997, 12, 306-317.
13. Cushman, M.; Sherman, P. Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogues, and polymer fractions. Biochem. Biophys. Res. Commun. 1992, 185, 85-90.
14. Fesen, M. R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J.; Kohn, K. W. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pharmacol. 1994, 48, 595-608.
15. LaFemina, R. L.; Graham, P. L.; LeGrow, K.; Hastings, J. C.; Wolfe, A.; Young, S. D.; Emini, E. A.; Hazuda, D. J. Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrob. Agents Chemother. 1995, 39, 320-324.
16. Ojwang, J. O.; Buckheit, R. W.; Pommier, Y.; Mazumder, A.; deVreese, K.; Este, J. A.; Reymen, D.; Pallansch, L. A.; Lackman-Smith, C.; Wallace, T. L.; deClercq, E.; McGrath, M. S.; Rando, R. F. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1995, 39, 2426-2435.
17. Farnet, C.; Wang, B.; Lipford, J. R.; Bushman, F. D. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 9742-9747.
18. Burke, T. R.; Fesen, M. R.; Mazumder, A.; Wang, J.; Carothers, A. M.; Grunberger, D.; Driscoll, J.; Kohn, K.; Pommier, Y. Hydroxylated aromatic inhibitors of HIV-1 integrase. J. Med. Chem. 1995, 38, 4171-4178.
19. Dotan, I.; Scottoline, B. P.; Heuer, T. S.; Brown, P. O. Characterization of recombinant murine leukemia virus integrase. J. Virol. 1995, 69, 456-468.
20. Chow, S. A.; Brown, P. O. Substrate features important for recognition and catalysis by human immunodeficiency virus type 1 integrase identified by using novel DNA substrates. J. Virol. 1994, 68, 3896-907.
21. Chow, S. A.; Vincent, K. A.; Ellison, V.; Brown, P. O. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 1992, 255, 723-726.
22. Bushman, F. D.; Engelman, A.; Palmer, I.; Wingfield, P.; Craigie, R. Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 3428-3432.
23. Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Engelman, A.; Craigie, R.; Davies, D. R. Crystal structure of the catalytic domain of HTV-1 integrase: similarity to other polynucleotidyl transferases [see comments]. Science 1994, 266, 1981-1986.
24. Eich, E.; Pertz, H.; Kaloga, M.; Schulz, J.; Fesen, M. R.; Mazumder, A.; Pommier, Y. (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase. J. Med. Chem. 1996, 39, 86-89.
25. Mazumder, A.; Wang, S.; Neamati, N.; Nicklaus, M.; Sunder, S.; Chen, J.; Milne, G. W. A.; Rice, W. G.; Burke, T. R., Jr.; Pommier, Y. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. J. Med. Chem. 1996, 39, 2472-2481.
26. King, P. J.; Robinson, W. E., Jr. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J. Virol. 1998, 72, 8420-8424.
27. Fesen, M. R.; Kohn, K. W.; Leteurtre, F.; Pommier, Y. Inhibitors of human immunodeficiency virus integrase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 2399-2403.
28. Mazumder, A.; Gazit, A.; Levitzki, A.; Nicklaus, M.; Yung, J.; Kohlhagen, G.; Pommier, Y. Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Biochemistry 1995, 34, 15111-15122.
29. Zhao, H.; Neamati, N.; Mazumder, A.; Sunder, S.; Pommier, Y.; Burke, T. R., Jr. Arylamide inhibitors of HFV-1 integrase. J. Med. Chem. 1997, 40, 1186-1194.
30. Mahmood, N.; Moore, P. S.; De Tommasi, N.; De Simone, F.; Colman, S.; Hay, A. J.; Pizza, C. Inhibition of HIV infection by caffeoylquinic acid derivatives. Antiviral. Chem. Chemother. 1993, 4, 235-240.
31. Lubkowski, J.; Yang, F.; Alexandratos, J.; Wlodawer, A.; Zhao, H.; Burke, T. R., Jr.; Neamati, N.; Pommier, Y.; Merkel, G.; Skalka, A. M. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4831-4836.
32. Neamati, N.; Mazumder, A.; Sunder, S.; Owen, J. M.; Tandon, M.; Lown, J. W.; Pommier, Y. Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as inhibitors of human immunodeficiency virus type 1 integrase. Mol. Pharmacol. 1998, 54, 280-290.
33. Mekouar, K.; Mouscadet, J.-F.; Desmaele, D.; Subra, F.; Leh, H.; Savoure, D.; Auclair, C.; d'Angelo, J. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem. 1998, 41, 2846-2857.
34. Bujacz, G.; Alexandratos, J.; Zhou-Liu, Q.; Clement-Mella, C.; Wlodawer, A. The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutant. FEBS Lett. 1996, 398, 175-178.
35. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R.; Davies, D. R. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9150-9154.
36. Scarpati, M. L.; Oriente, G. Chicoric acid (dicaffeoyltartaric acid): its isolation from chicory (Chicorium intybus) and synthesis. Tetrahedron 1958, 4, 43-48.
37. Cheminat, A.; Zawatzky, R.; Becker, H.; Brouillard, R. Caffeoyl conjugates from Echinacea species: structures and biological activity. Phytochemistry 1988, 27, 2787-2794.
38. Breitmaier, E.; Voelter, W. Carbon-13 NMR Spectroscopy; VCH Publishing: New York, 1987.
39. Veit, M.; Strack, D.; Czygan, F.-C.; Wray, V.; Witte, L. Di-E-caffeoyl-meso-tartaric acid in the barren sprouts of Equisetum arvense. Phytochemistry 1991, 30, 527-529.
40. Jackman, J. M.; Sternhell, S. Applications of Modern Magnetic Resonance Spectroscopy in Organic Chemistry, 2nd ed.; Pergamon Press: New York, 1969; pp 238-241.
41. Matsuta, M.; Kanita, R.; Saito, U.; Yamashita, A. The 3α-hydroxysteroid dehydrogenase inhibitory active flavonoids and phenylpropanoids from Schizonepeta spikes. Natural Med. 1996, 50, 204-211.
42. Li, L.-N. New depsides from Salvia species. Youji Huaxue 1993, 13, 303-304.
43. Ichikawa, K.; Sakurai, Y.; Akiyama, T.; Yoshioka, S.; Shiraki, T.; Horikoshi, H.; Kuwano, H.; Kinoshita, T.; Boriboon, M. Isolation and structure determination of aldose reductase inhibitors from traditional Thai medicine and syntheses of their derivatives. Sankyo Kenkyusho Nempo 1991, 43, 99-110.
44. Montefiori, D. C.; Robinson, W. E., Jr.; Schuffman, S. S.; Mitchell, W. M. Evaluation of antiviral drugs and neutralizing antibodies against human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 1988, 26, 231-235.
45. Robinson, W. E., Jr.; Montefiori, D. C.; Gillespie, D. H.; Mitchell, W. M. Complement-mediated, antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro increases HIV-1 RNA and protein synthesis and infectious virus production. J. Acq. Imm. Def. Syndr. 1989, 2, 33-42.
46. Hazuda, D.; Felock, P.; Hastings, J.; Pramanik, B.; Wolfe, A.; Goodarzi, G.; Vora, A.; Brackmann, K.; Grandgenett, D. Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds. J. Virol. 1997, 71, 807-811.
47. Hazuda, D. J.; Felock, P. J.; Hastings, J. C.; Pramanik, B.; Wolfe, A. L. Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J. Virol. 1997, 71, 7005-7011.